A Retrospective Study to Investigate Safety of Receiving Interleukin-17 Monoclonal Antibody for Psoriasis Patients With Hepatitis B Virus

IF 3.7 4区医学 Q1 DERMATOLOGY Dermatologic Therapy Pub Date : 2025-02-27 DOI:10.1155/dth/8942831

Haohao Wu, Juan Wang, Min Zhang, Jing Peng, Yi You

{"title":"A Retrospective Study to Investigate Safety of Receiving Interleukin-17 Monoclonal Antibody for Psoriasis Patients With Hepatitis B Virus","authors":"Haohao Wu, Juan Wang, Min Zhang, Jing Peng, Yi You","doi":"10.1155/dth/8942831","DOIUrl":null,"url":null,"abstract":"<div>\n Background: The increasing utilization of interleukin-17 (IL-17) monoclonal antibody (MA) for psoriasis treatment, coupled with the high prevalence of hepatitis B virus (HBV), underscores the need for comprehensive safety data. This retrospective study aims to evaluate the safety of IL-17 MA treatment in psoriasis patients with concurrent HBV infection.\n Research Design and Methods: The study screened 531 psoriasis patients treated with IL-17 MA, ultimately enrolling 59 patients with abnormal HBV serological data. Outcomes assessed include HBV virological reactivation and changes in HBsAb serum quantification post-IL-17 MA therapy.\n Results: Laboratory data revealed HBV virological reactivation in two psoriasis patients classified as inactive HBV carriers (IBCs). Patients who had previously received HBV vaccination exhibited a significant decrease in HBsAb serum quantification following IL-17 MA therapy.\n Conclusion: IL-17 MA therapy presents a potential risk of HBV reactivation in psoriasis patients with HBV infection. Furthermore, IL-17 MA appears to weaken HBV resistance in vaccinated patients.\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8942831","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/8942831","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The increasing utilization of interleukin-17 (IL-17) monoclonal antibody (MA) for psoriasis treatment, coupled with the high prevalence of hepatitis B virus (HBV), underscores the need for comprehensive safety data. This retrospective study aims to evaluate the safety of IL-17 MA treatment in psoriasis patients with concurrent HBV infection.

Research Design and Methods: The study screened 531 psoriasis patients treated with IL-17 MA, ultimately enrolling 59 patients with abnormal HBV serological data. Outcomes assessed include HBV virological reactivation and changes in HBsAb serum quantification post-IL-17 MA therapy.

Results: Laboratory data revealed HBV virological reactivation in two psoriasis patients classified as inactive HBV carriers (IBCs). Patients who had previously received HBV vaccination exhibited a significant decrease in HBsAb serum quantification following IL-17 MA therapy.

Conclusion: IL-17 MA therapy presents a potential risk of HBV reactivation in psoriasis patients with HBV infection. Furthermore, IL-17 MA appears to weaken HBV resistance in vaccinated patients.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.